meningococcal A C Y and W-135 polysaccharide vaccine combined (Menomune A/C/Y/W-135)

Dosing and uses of Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined)

• Adult
• Pediatric

 

Adult dosage forms and strengths

vaccine

• 0.5mL/vial

 

Meningococcal Vaccination

Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged 2 years or older

ACIP recommendations: Preferred vaccine for adults ≥56 yr who have not received MenACWY conjugate vaccine (Menactra, Menveo) previously and who require a single dose only (eg, travelers)

0.5 mL SC as a single dose

Up-to-date vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.htmL

 

Dosing Considerations

MenACWY conjugate vaccine (Menactra, Menveo) preferred for outbreak situations and high risk individuals

 

Administration

Preferably in deltoid region

 

Pediatric dosage forms and strengths

vaccine

• 0.5mL/vial

 

Immunization

Indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in persons aged 2 years or older

Although approved by the FDA for children ≥2 yr, ACIP pediatric vaccination guidelines do not include the polysaccharide vaccine (Menomune)

<2 years: Safety and efficacy not established

0.5 mL SC as a single dose

Up-to-date vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.htmL

 

Dosing Considerations

MenACWY conjugate vaccine (Menactra, Menveo) preferred for outbreak situations and high risk individuals

 

Administration

Preferable in deltoid region

 

Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined) adverse (side) effects

Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

 

>10%

Anorexia

Arthralgia

Diarrhea

Fatigue

Headache

Induration

Malaise

Pain

Redness

Swelling

 

1-10%

Chills

Fever

Rash

Vomiting

 

Warnings

Contraindications

Hypersensitivity to any component, including dry natural rubber latex (present in vial stopper)

 

Cautions

A few cases of Guillain Barre syndrome reported following administration, causality unknown

Not indicated for N. meningitidis serogroup B

Patients with bleeding disorder

Immunosuppressed patients

 

Pregnancy and lactation

Pregnancy category: C

Lactation: use caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Menomune A/C/Y/W-135 (meningococcal A C Y W-135 polysaccharide vaccine combined)

Mechanism of action

Meningococcal serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein carrier

These products convey active immunity via stimulation of production of endogenously produced antibodies